重组人血小板生成素促进严重全身照射后的造血重建。
Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation.
作者信息
Wang Chao, Zhang Bowen, Wang Sihan, Zhang Jing, Liu Yiming, Wang Jingxue, Fan Zeng, Lv Yang, Zhang Xiuyuan, He Lijuan, Chen Lin, Xia Huanzhang, Li Yanhua, Pei Xuetao
机构信息
Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, Beijing 100850, China.
School of Life Science and Bio Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
出版信息
Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993.
Recombinant human thrombopoietin (rHuTPO) is a drug that is used clinically to promote megakaryocyte and platelet generation. Here, we report the mitigative effect of rHuTPO (administered after exposure) against severe whole body irradiation in mice. Injection of rHuTPO for 14 consecutive days following exposure significantly improved the survival rate of lethally irradiated mice. RHuTPO treatment notably increased bone marrow cell density and LSK cell numbers in the mice after sub-lethal irradiation primarily by promoting residual HSC proliferation. In lethally irradiated mice with hematopoietic cell transplantation, rHuTPO treatment increased the survival rate and enhanced hematopoietic cell engraftment compared with the placebo treatment. Our observations indicate that recombinant human TPO might have a therapeutic role in promoting hematopoietic reconstitution and HSC engraftment.
重组人血小板生成素（rHuTPO）是一种临床上用于促进巨核细胞和血小板生成的药物。在此，我们报告了rHuTPO（照射后给药）对小鼠严重全身照射的缓解作用。照射后连续14天注射rHuTPO可显著提高致死性照射小鼠的存活率。rHuTPO治疗主要通过促进残留造血干细胞增殖，显著增加了亚致死照射小鼠的骨髓细胞密度和LSK细胞数量。在接受造血细胞移植的致死性照射小鼠中，与安慰剂治疗相比，rHuTPO治疗提高了存活率并增强了造血细胞植入。我们的观察结果表明，重组人血小板生成素在促进造血重建和造血干细胞植入方面可能具有治疗作用。
Zotero 插件